Unicycive Therapeutics Faces Class Action Lawsuit: A Call for Action from Investors
Unicycive Therapeutics Faces Class Action Lawsuit
Unicycive Therapeutics, Inc., known by its NASDAQ ticker UNCY, is currently under scrutiny due to a class-action lawsuit initiated by investors. This legal action, prompted by concerns over the company's disclosure practices, affects shareholders who purchased securities between December 29, 2025, and June 29, 2026.
Allegations Against Unicycive
The lawsuit alleges that Unicycive misled its shareholders by claiming that its application for the drug oxylanthanum carbonate (OLC) was progressing smoothly. Notably, it is claimed that the company provided these reassurances while failing to independently verify that the third-party manufacturer responsible for OLC had addressed issues highlighted by the FDA in prior reviews. The company had informed investors about a resubmission of its drug application, stating that it was reliant on
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.